There has never been a trigger for speed and agility in life sciences as critical and immense as the Novel Coronavirus COVID-19. The pressure to deliver across the entire value chain is paramount, with entire businesses and lives hanging in the balance. More than ever, the mantras of digitization, automation, and direct to consumer are becoming obvious answers.
Life-sciences companies can seize the opportunity to connect with their customers, both providers and patients, in new ways. Download the paper and see where our experts think the industry could be going.
Prediction 1: R&D will seize the moment to embrace new discovery and delivery models and to change how the world views clinical trials
Prediction 2: The democratization of healthcare to consumers will accelerate, leading to digital-first innovations in sales and marketing
Prediction 3: Supply-chain agility will support the reimagining of business models
Prediction 4: The need for speed will force regulators to adopt more risk
Prediction 5: Digital surveillance becomes the new normal
Connect with us
Thank you for your interest in Capgemini.
We are sorry, the form submission failed. Please try again.